The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
Launched by MILESTONE PHARMACEUTICALS INC. · Nov 20, 2017
Trial Information
Current as of April 25, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- A participant must meet all of the following criteria to be eligible for participation in the study:
- • Adult male or female.
- • Participant has suspected PSVT as per the online prescreening assessment.
- • Participant lives in a country in which the registry is being conducted.
- • Participant has signed the informed consent form indicating he/she is able to complete the online registry data collection forms on his/her own.
- Exclusion Criteria:
- • Participant does not have an email address.
- • Participant does not set up a user account.
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. With a commitment to addressing unmet medical needs, Milestone specializes in the advancement of novel treatments that aim to improve patient outcomes and enhance quality of life. The company is dedicated to rigorous clinical research and development, driven by a team of experienced professionals who strive to bring safe and effective solutions to market. Through strategic collaborations and a patient-centric approach, Milestone Pharmaceuticals is poised to make significant contributions to the field of cardiovascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Trial Officials
Douglas Wight
Study Director
Milestone Pharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials